Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial
Digital
- Autores:
-
Raubenheimer, Peter J.
Cushman, William C.
Avezum, Alvaro
Basile, Jan
Conget, Ignacio
Dagenais, Gilles
Hoover, Anastasia
Jansky, Petr
Lanas, Fernando
Leiter, Lawrence A.
Lopez-Jaramillo, Patricio
Pogosova, Nana
Probstfield, Jeffrey
Rao-Melacini, Purnima
Ryden, Lars
Sheu, Wayne H.-H.
Temelkova-Kurktschiev, Theodora
Gerstein, Hertzel C.
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2022
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/6086
- Palabra clave:
- Rights
- closedAccess
- License
- © The Authors, John Wiley & Sons Ltd. 2022
id |
RUDES2_90d1c4976d1ded2ddd57846038a39e9f |
---|---|
oai_identifier_str |
oai:repositorio.udes.edu.co:001/6086 |
network_acronym_str |
RUDES2 |
network_name_str |
Repositorio Universidad de Santander |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial |
title |
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial |
spellingShingle |
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial |
title_short |
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial |
title_full |
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial |
title_fullStr |
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial |
title_full_unstemmed |
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial |
title_sort |
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial |
dc.creator.fl_str_mv |
Raubenheimer, Peter J. Cushman, William C. Avezum, Alvaro Basile, Jan Conget, Ignacio Dagenais, Gilles Hoover, Anastasia Jansky, Petr Lanas, Fernando Leiter, Lawrence A. Lopez-Jaramillo, Patricio Pogosova, Nana Probstfield, Jeffrey Rao-Melacini, Purnima Ryden, Lars Sheu, Wayne H.-H. Temelkova-Kurktschiev, Theodora Gerstein, Hertzel C. |
dc.contributor.author.none.fl_str_mv |
Raubenheimer, Peter J. Cushman, William C. Avezum, Alvaro Basile, Jan Conget, Ignacio Dagenais, Gilles Hoover, Anastasia Jansky, Petr Lanas, Fernando Leiter, Lawrence A. Lopez-Jaramillo, Patricio Pogosova, Nana Probstfield, Jeffrey Rao-Melacini, Purnima Ryden, Lars Sheu, Wayne H.-H. Temelkova-Kurktschiev, Theodora Gerstein, Hertzel C. |
dc.contributor.researchgroup.spa.fl_str_mv |
Masira |
description |
Digital |
publishDate |
2022 |
dc.date.accessioned.none.fl_str_mv |
2022-02-21T20:58:39Z |
dc.date.available.none.fl_str_mv |
2022-02-21T20:58:39Z |
dc.date.issued.none.fl_str_mv |
2022-01-04 |
dc.type.spa.fl_str_mv |
Artículo de revista |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.content.spa.fl_str_mv |
Text |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
http://purl.org/coar/resource_type/c_6501 |
status_str |
publishedVersion |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1111/dom.14634 |
dc.identifier.uri.none.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/6086 |
url |
https://doi.org/10.1111/dom.14634 https://repositorio.udes.edu.co/handle/001/6086 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationissue.spa.fl_str_mv |
4 |
dc.relation.citationvolume.spa.fl_str_mv |
23 |
dc.relation.indexed.spa.fl_str_mv |
Scopus |
dc.relation.ispartofjournal.spa.fl_str_mv |
Diabetes, Obesity and Metabolism |
dc.rights.spa.fl_str_mv |
© The Authors, John Wiley & Sons Ltd. 2022 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_14cb |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/closedAccess |
dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
rights_invalid_str_mv |
© The Authors, John Wiley & Sons Ltd. 2022 Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_14cb |
eu_rights_str_mv |
closedAccess |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Diabetes, Obesity and Metabolism |
dc.publisher.place.spa.fl_str_mv |
Reino Unido |
dc.source.spa.fl_str_mv |
https://dom-pubs.onlinelibrary.wiley.com/doi/epdf/10.1111/dom.14634 |
institution |
Universidad de Santander |
bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/822375db-8f67-4737-ab25-bf711d73b662/download https://repositorio.udes.edu.co/bitstreams/92d08648-b614-43dd-97c3-f481b997a1a0/download https://repositorio.udes.edu.co/bitstreams/6e8981f5-1c6c-4df2-a1d4-17e3326684c1/download https://repositorio.udes.edu.co/bitstreams/4d29ea38-4f7e-428c-b99b-985ea0d20562/download |
bitstream.checksum.fl_str_mv |
aa2371097f345c34904e34901f99d039 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 913f3f27e87e55f77753a7eae5667a59 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Universidad de Santander |
repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
_version_ |
1814158970957332480 |
spelling |
Raubenheimer, Peter J.260f749c-e594-4273-a34d-e926010f883c-1Cushman, William C.6e873915-69b2-4696-afa0-6d21bbeb3531-1Avezum, Alvaro8b920360-abb2-4ec8-b5ee-4e3f4e0b11eb-1Basile, Jan31df2eea-b661-4757-98a0-111336270810-1Conget, Ignacioc0327a53-3097-438b-9a40-d441f3c20758-1Dagenais, Gillesc865f015-4dc7-483d-9dae-132288d901f8-1Hoover, Anastasia4af8a82b-9f2a-4b54-97b6-f0d2a9d846d8-1Jansky, Petrbf8ec62a-6edc-439c-a698-2e4fa4172f04-1Lanas, Fernandod22b7fe4-9f1f-4028-a22b-be782ef03d3c-1Leiter, Lawrence A.bcdd3211-40b7-474d-9f6c-8a1051ceb9bf-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Pogosova, Nana0f2fb5e5-6659-4562-96e6-74c03e0c46bf-1Probstfield, Jeffreycce7af47-ba6b-4280-bbb5-4c0a46da5d7d-1Rao-Melacini, Purnima4a704681-2187-4ddd-b2c1-f8e681c77274-1Ryden, Larse8666dad-aab3-446a-9e58-5e23a391873f-1Sheu, Wayne H.-H.d377b549-9728-486e-820f-f5e9d3ba834b-1Temelkova-Kurktschiev, Theodoraa08e998d-95f2-4139-ae16-bd8009965b60-1Gerstein, Hertzel C.8dbb4c88-f0dd-45f2-8bc4-590f0a1e3c3c-1Masira2022-02-21T20:58:39Z2022-02-21T20:58:39Z2022-01-04DigitalAim To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide versus placebo. Materials and Methods Patients without electrocardiographic (ECG)-confirmed AA at baseline and randomized in the REWIND trial were assessed for the development of AA based on an annual ECG. Additional analyses included whether dulaglutide compared with placebo reduced the composite outcome of AA or death, AA or cardiovascular death, AA or stroke and AA or heart failure. Results Among 9543 participants (mean age 66 ± 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up. Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, versus 255 of the 4774 allocated to placebo (5.3%), at a rate of 10.5 per 1000 person-years (P = .59). There was also no effect of dulaglutide on the composite outcome of AA and death or AA and heart failure. Conclusion This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes.Ciencias Médicas y de la Saludapplication/pdfhttps://doi.org/10.1111/dom.14634https://repositorio.udes.edu.co/handle/001/6086engDiabetes, Obesity and MetabolismReino Unido423ScopusDiabetes, Obesity and Metabolism© The Authors, John Wiley & Sons Ltd. 2022info:eu-repo/semantics/closedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_14cbhttps://dom-pubs.onlinelibrary.wiley.com/doi/epdf/10.1111/dom.14634Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trialArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdfDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdfapplication/pdf258879https://repositorio.udes.edu.co/bitstreams/822375db-8f67-4737-ab25-bf711d73b662/downloadaa2371097f345c34904e34901f99d039MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/92d08648-b614-43dd-97c3-f481b997a1a0/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdf.txtDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/6e8981f5-1c6c-4df2-a1d4-17e3326684c1/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdf.jpgDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdf.jpgGenerated Thumbnailimage/jpeg7507https://repositorio.udes.edu.co/bitstreams/4d29ea38-4f7e-428c-b99b-985ea0d20562/download913f3f27e87e55f77753a7eae5667a59MD54001/6086oai:repositorio.udes.edu.co:001/60862023-10-09 16:51:29.74https://creativecommons.org/licenses/by-nc/4.0/© The Authors, John Wiley & Sons Ltd. 2022https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |